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OBJECTIVES: This study evaluated the effect of Continuous Positive Airway Pressure treatment on oxidative stress
parameters and the quality of life of elderly patients with obstructive sleep apnea syndrome.
METHODS: In total, 30 obstructive sleep apnea syndrome patients and 27 subjects without obstructive sleep apnea
syndrome were included in this study. Both groups underwent quality of life and oxidative stress evaluations at
baseline and after six months. Polysomnography was performed in both groups at baseline and a second time in the
obstructive sleep apnea syndrome group after six months of Continuous Positive Airway Pressure treatment. All of
the variables were compared between the control and obstructive sleep apnea syndrome groups in this prospective
case-control study.
RESULTS: The baseline concentrations of the antioxidant enzyme catalase were higher in the obstructive sleep
apnea syndrome group than the control group. After Continuous Positive Airway Pressure treatment, the
obstructive sleep apnea syndrome group exhibited a reduction in the level of oxidative stress, as indicated by a
decrease in the level of lipid peroxidation measured by the malondialdehyde (MDA) concentration [pre: 2.7 nmol
malondialdehyde/mL (95% 1.6-3.7) vs. post: 1.3 nmol MDA/mL (0.7-1.9), p,0.01]. Additionally, improvements were
observed in two domains covered by the SF-36 questionnaire: functional capacity [pre: 77.4 (69.2-85.5) vs. post: 83.4
(76.9-89.9), p= 0.002] and pain [pre: 65.4 (52.8-78.1) vs. post: 77.8 (67.2-88.3), p= 0.004].
CONCLUSION: Our study demonstrated that the use of Continuous Positive Airway Pressure to treat obstructive
sleep apnea syndrome in elderly patients reduced oxidative stress and improved the quality of life.
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INTRODUCTION
Obstructive sleep apnea syndrome (OSAS) manifests as a
reduction (hypopnea) or complete cessation (apnea) of
airflow, which causes an increase in inspiratory effort that
often culminates in arousal (1). OSAS is characterized by
the collapse of the extrathoracic airway (2,3), a transient
decrease in oxyhemoglobin saturation, hypercapnia, and
consequent hyperventilation. These symptoms affect the
objective and subjective qualities of sleep and trigger
characteristic clinical symptoms, such as excessive daytime
sleepiness (4,5). Several factors, including male gender,
older age, obesity, alcohol use, otorhinolaryngological
changes (6,7) and heredity, are associated with the pre-
valence, increased risk, and severity of OSAS (8,9).
The consequences of OSAS, such as accidents caused by
excessive daytime sleepiness (10), increased risk of cardio-
vascular diseases (11) and mood and metabolic alterations
(12,13), have been widely studied. OSAS also increases the
generation of reactive oxygen species (ROS). The over-
production of ROS results in oxidative stress (OS), which
results in damage to cellular structures, including lipids,
membranes, proteins and DNA (14). OS produces a cascade
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of events that trigger inflammation, an increase in sympa-
thetic tonus, vascular endothelial dysfunction, metabolic
alterations, and/or increased platelet aggregation (15,16).
The chronic intermittent hypoxia, sleep loss and fragmenta-
tion experienced by OSAS patients may be related to
endothelial dysfunction due to the increases in the levels
of inflammatory mediators, OS and coagulant activity.
Endothelial dysfunction contributes to the development of
atherosclerosis and OSAS-associated cardiovascular disor-
ders. However, OSAS comorbidities and metabolic syn-
drome are also associated with endothelial dysfunction.
OSAS may also induce or exacerbate various aspects of
metabolic syndrome, such as glucose metabolism, choles-
terol, inflammatory markers, and nonalcoholic fatty liver
disease (17-21).
The use of Continuous Positive Airway Pressure (CPAP)
is an effective treatment for OSAS because CPAP normalizes
the sleep architecture, reduces subjective excessive daytime
sleepiness and reverses other OSAS symptoms (22). CPAP
treatment prevents hypoxia and oxygenation injury,
decreases OS and inhibits the cascade of deleterious
OSAS-induced consequences (23,24). Patients with severe
OSAS and metabolic syndrome who exhibit good compli-
ance with CPAP treatment may exhibit improved insulin
sensitivity and reduced systemic inflammation, OS, and
global cardiovascular disease risk (25).
Aging predisposes people to OSAS. The prevalence of
OSAS is higher in elderly populations than in young adults
(26). The prevalence of an apnea hypopnea index (AHI) .15
events per hour among 60- to 69-year-old males was 52.3%
in Sa˜o Paulo city, Brazil, and this frequency increased to
84.7% among 70- to 80-year-old males (27).
The literature highlights the positive effects of CPAP on
excessive daytime sleepiness in adults and reports variable
responses with respect to cardiovascular and cognitive
functions; however, the impact of OSAS on the cardiovas-
cular system in the elderly population is controversial (28,29).
The aims of this study were to compare OS parameters
and the quality of life in elderly patients between
individuals with and without OSAS and to evaluate the
effect of CPAP treatment on OSAS patients.
METHODS
This study was approved by the ethics committee of the
Universidade Federal de Sa˜o Paulo (CEP: 1977/09). All of
the patients signed an informed consent form.
Patients and Study Design
This prospective case-control study evaluated consecutive
patients with suspected OSAS who were seen at the
outpatient sleep clinic. The diagnosis of OSAS was confirmed
using polysomnography (PSG) if the AHI was $20. Patients
were compared with age-matched subjects without OSAS
(AHI#10). These cut-off values were based on previous
publications on OSAS in elderly patients (30,31).
The inclusion criteria were as follows: age between 60 and
75 years (32,33), male gender, and a body mass index (BMI)
less than 35 kg/m2. Subjects in the OSAS group exhibited
clinical criteria of this syndrome (34) and an AHI of $20
events per hour; the AHI was #10/h in the control group.
The protocol excluded individuals who had neurological or
psychiatric diseases, sleep disorders other than OSAS,
alcohol abuse and/or psychoactive drug use. Patients who
had previously received treatment for OSAS were also
excluded.
Subjects underwent an assessment protocol at baseline
that used the following tools: a questionnaire that is
routinely used in our sleep laboratory (35), the Epworth
Sleepiness Scale (ESS) (36), a quality of life questionnaire
(SF – 36) (37), laboratory tests and PSG. The PSG results and
clinical symptoms divided the subjects into two groups (i.e.,
the presence or absence of OSAS). The OSAS group received
six months of CPAP treatment, and the control subjects
received no intervention. The OSAS group was submitted to
PSG with CPAP at the end of the study. Both groups
completed all of the other assessments at baseline at the end
of the study (Figure 1).
Polysomnography
Full-night PSG was performed using a digital system
(EmblaH S7000, Embla Systems, Inc., Broomfield, CO, USA),
and the following parameters were measured: electroence-
phalography, electromyography, electrocardiography, oral
and nasal breathing (thermistor and pressure transducer),
thoracic and abdominal respiratory effort (inductive
plethysmography), snoring, oxyhemoglobin saturation,
and body position. We used the Rechtschaffen and Kales
criteria to score sleep (38). Respiratory events were assessed
according to the American Academy of Sleep Medicine Task
Force (1). Arousals (39) and periodic leg movements (40)
were described according to the American Sleep Disorders
Association criteria.
CPAP
All of the patients in the OSAS group underwent a full-
night PSG to titrate the CPAP pressure. Each patient
received a CPAP system (REMstarH Plus, Respironics, Inc.,
Murrysville, Pennsylvania, USA) after researchers deter-
mined the ideal pressure for treatment. The CPAP system
had an hour meter to control the duration of the positive
pressure.
The patients also participated in an educational program
on CPAP use that included four visits by trained staff. Visits
occurred one week and one, three, and six months after the
initial treatment.
Laboratory Analysis
Venous blood for laboratory evaluations of OS parameters
was collected in heparin-containing tubes in the morning after
volunteers had fasted for twelve hours. Plasma and red blood
cells were separated and properly stored for the evaluation of
biochemical parameters (41). Spectrophotometry (Hitachi U-
3900/3900H, Tokyo, Japan) was used to determine the levels
of malondialdehyde (MDA, expressed in nmol MDA/mL),
Figure 1 - Study Design.
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erythrocyte catalase (CAT) activity (expressed in U/mg
hemoglobin), and superoxide dismutase (SOD) activity in
erythrocytes (expressed as U/mg Hb).
A competitive immunoassay using direct chemilumines-
cence was used to determine the vitamin B12 and folate
concentrations (ADVIA CentaurH/Siemens Healthcare
Diagnostics, Inc., Deerfield, Illinois, USA). The folate
concentrations are expressed as nmol/L, and the vitamin
B12 concentrations are expressed as pmol/L.
High-performance liquid chromatography (HPLC) (Shi-
madzu with fluorescence detector RF-10AXL, Kyoto, Japan)
with fluorometric detection and isocratic elution was used to
measure the levels of plasma homocysteine (Hcy) and cysteine
(Cys) (both are expressed in mmol/L). The uric acid values
were measured using the uricase-enzymatic colorimetric
method (AdviaH 1650/2400/Siemens Healthcare Diagnostics,
Inc., Deerfield, Illinois, USA). The results are expressed as mg/
dL. To determine the concentrations of vitamins C and E, we
used an HPLC-UV system according to the Immundiagnostik
method. The results are expressed in mmol/L.
Statistical Analysis
Statistical analysis was performed using SPSS version
13.0 for Windows. Descriptive analysis (means¡standard
errors) was used to characterize the groups. The results of
the PSG, the questionnaire answers and the OS parameters
were assessed using a general linear model (GLM) with
repeated measures. This analysis assessed the effects of
time, independent groups and control variables of interest.
BMI was a covariate in this analysis to prevent bias because
an association among obesity, OSAS and OS has been
demonstrated previously.
We standardized the data using the Z score. The nonpara-
metric Mann-Whitney test was used to compare independent
groups, and the Wilcoxon test was used for repeated
measures. Effect sizes (Partial Eta Squared - Eta2) and the
observed power were also considered to prevent type I and
type II errors. Statistical significance was set at 5% (p,0.05).
RESULTS
In total, 30 OSAS patients and 27 age-matched control
subjects were included in this study. Both groups (control
and OSAS) were homogeneous with respect to age (66.4¡0.7
years vs. 66.4¡0.7 years, respectively; p= 0.97), but the OSAS
group had a higher mean BMI than the control group
(25.1¡0.7 kg/m2 (control) vs. 27.9¡0.7 kg/m2 (OSAS);
p= 0.004) (Table 1). The important comorbidities of both
groups are presented in Table 2. No differences with respect
to the frequencies of hypothyroidism, diabetes and dyslipi-
demia were observed between the groups; however, the
prevalence of hypertension was higher in the OSAS group.
A multivariate analysis was used to evaluate the ques-
tionnaire responses at baseline, and the nonparametric
Mann-Whitney test confirmed the results of this analysis.
The OSAS group had a trend of higher ESS scores and worse
quality of life, with lower scores for ‘‘Functional Capacity’’
(79.7¡3.1 vs. 89.8¡2.8; p= 0.02) and ‘‘Pain’’ (68.6¡5 vs.
82.7¡4.5; p = 0.04) compared with the control group. A
tendency toward a lower score for ‘‘General Heath’’ was
observed in the OSAS group (Table 3).
All of the factors exhibited overlapping confidence
intervals in the repeated measures analysis of the two
groups. However, because the groups were heterogeneous
and because there was an insufficient number of cases, we
used the Wilcoxon test and divided the level of significance
by two. This test showed that there were improvements in
‘‘Functional Capacity’’ (p = 0.002) and ‘‘Pain’’ on the SF-36
(p= 0.004) (Table 3).
Multivariate analyses of all of the PSG variables at baseline
demonstrated a high effect size (Eta2 = 0.79) and a strong
observed power (p= 1.00). BMI was used as a covariant.
Relative to the control group, the OSAS group exhibited
significant differences with respect to variables related to
light sleep (increased percentage in stage 2 of NREM sleep)
(60.3¡2.5% vs. 53¡2.3%; p= 0.04) and higher arousal rates
(27.1¡2.4 per hour vs. 11.8¡2.2 per hour; p,0.01). In
addition, the OSAS group had a higher AHI (37.8¡2.3 per
hour vs. 5.3¡2.1 per hour; p,0.01) and lower minimum and
mean oxyhemoglobin saturation levels (76.7¡2% vs.
87.9¡1.8%; p,0.01 and 91.2¡0.8% vs. 94.2¡0.8%; p,0.05,
respectively) than controls. The OSAS group also spent more
time with oxyhemoglobin saturation levels below 90%
(22.9¡4.6% vs. 1.19¡3.3%; p,0.01) (Table 1).
PSG was performed a second time in the OSAS group to
evaluate the effect of the CPAP treatment. The PSG perfor-
mance after treatment revealed a decrease in the percentage
Table 1 - Baseline polysomnographic and clinical data for
the control and obstructive sleep apnea syndrome (OSAS)
groups.
Control OSAS p-value
Age 66.4¡0.7 66.4¡0.7 0.97
BMI (kg/m2) 25.1¡0.7 27.9¡0.7 ,0.001
Sleep Lat (min) 23.8¡6.1 18.2¡6.6 0.53
REM Lat (min) 98.0¡11.7 81.2¡12.7 0.34
TST (min) 336.3¡15.5 327.6¡16.9 0.71
SE (%) 75.4¡3.0 75.4¡3.3 1.00
S1 (%) 8.9¡1.8 6.1¡1.9 0.30
S2 (%) 53.0¡2.3 60.3¡2.5 0.04
S3+4 (%) 18.6¡1.5 15.1¡1.6 0.13
REM Sleep (%) 19.7¡1.1 18.3¡1.2 0.44
Wake (min) 93.0¡12.1 103.3¡13.2 0.57
AI/h 11.8¡2.2 27.1¡2.4 ,0.001
PLM/h 6.3¡3.3 8.4¡3.6 0.67
AHI/h 5.3¡2.1 37.8¡2.3 ,0.001
Mean SpO2 (%) 94.2¡0.8 91.2¡0.8 0.02
Min SpO2 (%) 87.9¡1.8 76.7¡2.0 ,0.001
SpO2, 90% (min) 1.19¡3.3 22.91¡ 4.6 ,0.001
Data are expressed as the mean¡standard error (SE). BMI: body mass
index; Sleep Lat: sleep latency; REM Lat: REM sleep latency; TST: total
sleep time; SE: sleep efficiency; S1: stage 1; S2: stage 2; S3: stage 3; S3+4:
stage 3 and 4; REM Sleep: rapid eye movement sleep; Wake: minutes
awake; AI: arousal index; PLM: periodic leg movements; AHI: apnea/
hypopnea index; SpO2: saturation of oxyhemoglobin; SpO2,90%:
cumulative time during which the saturation of oxyhemoglobin was
below 90%. (GLM test).All of the OSAS patients of this study adhered to
the CPAP protocol for at least four hours per night, and the pressures
ranged from 8 to 15 cm H2O.
Table 2 - Number of individuals with relevant
comorbidities in both groups.
Control OSAS p-value
Hypothyroidism 14 3 NS
Dyslipidemia 7 12 NS
Diabetes 11 12 NS
Hypertension 29 60 0.03
Chi-square test.
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of stage 1 NREM sleep (5.8¡0.6% vs. 4.3¡0.5%; p,0.01), a
tendency toward an increase in the percentage of REM sleep
(18.1¡1.4% vs. 22¡1.5%; p=0.06), a decrease in minutes spent
awake (102.7¡17.3 min vs. 65¡11 min; p= 0.03), a decrease in
the rate of awakenings (25.6¡2.9 per hour vs. 10.4¡1.2 per
hour; p,0.01), a reduction in the AHI to within the normal
range (36.6¡3.4 per hour vs. 4¡0.9 per hour; p,0.01), and a
reduction in the duration of oxyhemoglobin saturation levels
below 90% (20.9¡8.6% vs. 0.8¡0.4%; p,0.05) compared with
baseline values. These changes were associated with objective
improvements in sleep quality (Table 4).
The CAT concentrations at baseline were higher in the
OSAS group than the control group [115.3 U/mg Hb (95% 88-
142) vs. 105.6 U/mg Hb (95% 67.8-143), respectively; p=0.004].
A significant increase in the vitamin C concentration was
observed for the control group [pre 56.5 mmol/L (95% 50.4-
62.7) vs. post 69.4 mmol/L (95% 63.2-75.7); p,0.01] and for the
OSAS group [pre 51.6 mmol/L (95% 44.0-59.2) vs. post 62.4
mmol/L (95% 54.7-70.1); p,0.01] at the final examination.
Higher CAT activity was observed in the OSAS group
compared with the control group [140.3 U/mg Hb (95%
115.0-165.0) vs. 50 U/mg Hb (95% 15.1-85.0)] at the final
evaluation. The use of CPAP treatment by the OSAS group
decreased the level of lipid peroxidation, which was
expressed in terms of the MDA concentration [pre: 2.7 nmol
MDA/mL (95% 1.6-3.7) vs. post: 1.3 nmol MDA/mL (0.7-1.9);
p,0.01] (Table 5).
No significant correlations between variables were
observed.
DISCUSSION
Our study demonstrated that the use of CPAP to treat OSAS
in elderly male patients contributed to a reduction in OS and
improved the quality of life. Oxidative damage and OSAS may
be related to aging. Similarly, a relationship may exist between
the reduction in antioxidant capacity and OSAS after CPAP
treatment. We demonstrated that CPAP was able to reverse
OS, as demonstrated by decreases in the MDA concentrations.
We also found that the CAT concentration increased in the
OSAS group after treatment. These results suggest that OSAS
may overload a patient’s antioxidant capacity, which increases
CAT activity. However, this augmentation of the antioxidant
enzyme activity was insufficient to cope with OSAS-induced
OS, and the lipid peroxidation levels were elevated in the
OSAS group prior to CPAP treatment. These results suggest
that lipid peroxidation may be an important pathological
event for these patients. Six months of CPAP treatment
increased the level of catalase activity, which suggests that the
antioxidant defense system was activated, and this mechan-
ism was able to reduce the level of lipid peroxidation levels in
OSAS patients during this period.
The association between aging and antioxidant capacity is
not well established, and no consensus has been reached
regarding the influence of aging on antioxidant capacity
(42,43). The increased CAT activity and reduced lipid
peroxidation observed in this study indicate the importance
of evaluating OS markers in OSAS patients. Therefore,
future studies should focus on improving the antioxidant
capacity of these patients.
An increase in the vitamin C concentration was observed
in both groups at the time of re-assessment relative to the
Table 3 - Baseline and final measures for sleepiness and quality of life for the control and obstructive sleep apnea
syndrome (OSAS) groups.
Control OSAS
Baseline Final Pre Post
ESS 8.8 (5.0-12.6) 7.9 (5.3-10.5) 10.7 (8.0-13.3) 7.4 (5.6-9.2) *
Functional Capacity 86.3 (76.0-96.5) 84.2 (76.0-92.3) 77.4 (69.2-85.5) ** 83.4 (76.9-89.9)
Physical 87.5 (70.5-104.5) 90.6 (71.1-110.1) 81.6 (68.0-95.1) 80.3 (64.8-95.8)
Pain 83.3 (67.4-99.3) 78.1 (64.8-91.4) 65.4 (52.8-78.1) ** 77.8 (67.2-88.3) *
Healthy 79.0 (68.2-89.8) 78.6 (69.7-87.5) 68.0 (59.4-76.6) 76.2 (69.1-83.2)
Vitality 71.7 (58.7-84.6) 73.8 (62.6-84.9) 70.1 (59.8-80.4) 68.7 (59.8-77.5)
Social Function 74.0 (58.8-89.1) 80.2 (65.0-95.4) 84.2 (72.2-96.3) 81.8 (69.7-93.9)
Emotional 63.8 (42.5-85.1) 80.5 (56.4-104.6) 80.1 (63.2-97.1) 78.9 (59.8-98.1)
Mental Health 70.3 (58.0-82.7) 73.6 (61.6-85.6) 80.0 (70.2-89.8) 80.0 (70.5-89.5)
Data are expressed as the mean (95% confidence interval). Scores are from the Epworth Sleepiness Scale (ESS) and the SF-36 questionnaire (domains:
Physical: role limitations due to physical problems; Pain: bodily pain; Health: general health perception; Vitality: energy/vitality; Social function: social
functioning; Emotional: role limitations due to emotional problems; Mental health: mental health).* p,0.05 compared with the baseline values for the
control group. ** p,0.05 compared with controls. (GLM, Mann Whitney and Wilcoxon tests).
Table 4 - Polysomnographic data before and after
Continuous Positive Airway Pressure treatment in the
obstructive sleep apnea syndrome (OSAS) group
OSAS
Before After p-value
Sleep Lat (min) 20.5¡5.8 12.6¡2.6 0.21
REM Lat (min) 69.5¡5.8 65.2¡8.0 0.64
TST(min) 326.7¡17.7 349.1¡11.3 0.25
SE (%) 75.5¡3.7 82.2¡2.3 0.08
S1 (%) 5.8¡0.6 4.3¡0.5 ,0.001
S2 (%) 59.6¡2.2 54.8¡2.4 0.12
S3+4 (%) 16.3¡1.7 18.8¡1.7 0.26
REM Sleep (%) 18.1¡1.4 22.0¡1.5 0.06
Wake (min) 102.7¡17.3 65.0¡11.0 0.05
AI/h 25.6¡2.9 10.4¡1.2 ,0.001
PLM/h 10.1¡5.5 10.8¡4.5 0.91
AIH/h 36.6¡3.4 4.0¡0.9 ,0.001
Mean SpO2 (%) 91.5¡1.4 94.7¡0.2 0.04
Min SpO2 (%) 76.9¡3.1 88.7¡0.5 ,0.001
SpO2, 90% (min) 20.9¡8.6 0.8¡0.4 0.04
Data are expressed as the mean¡standard error (SE). Sleep Lat: sleep
latency; REM Lat: REM sleep latency; TST: total sleep time; SE: sleep
efficiency; S1: stage 1; S2: stage 2; S3: stage 3; S3+4: stage 3 and 4; REM
Sleep: rapid eye movement sleep; Wake: minutes awake; AI: arousal
index; PLM: periodic leg movements; AHI: apnea/hypopnea index; SpO2:
saturation of oxyhemoglobin; SpO2, 90%: cumulative time during which
the saturation of oxyhemoglobin was below 90%. (GLM test).
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baseline levels. However, the concentrations were within
the normal range. These findings suggest that alterations in
the observed OS parameters are not related to vitamin C
availability.
The mean vitamin E concentrations in both groups (OSAS
and controls) were within the normal range (15 to 40 mmol/
L), which suggests that there is no effect of age on this
parameter.
One reason for the controversy regarding OS in the
literature may be that there are many protocols for assessing
OS, and researchers do not frequently follow the same
protocol. In addition to the variability in protocols, most of
the measures of OS markers are indirect measures, which
are less accurate (42-44).
The OSAS group exhibited a worse quality of life for two
domains of the SF-36 (‘‘Functional Capacity’’ and ‘‘Pain’’)
compared with the control group at baseline. The p-value
(0.051) for the difference in the ‘‘General Health’’ domain
was not statistically significant, but a trend toward
improvement in this domain was observed. Therefore,
repeating this study with a larger sample size may detect
an improvement in this domain. CPAP treatment improved
‘‘Functional Capacity’’ and ‘‘Pain’’. Improvement reflected
by the SF-36 after CPAP treatment has been reported
previously in adults (45). However, OSAS did not suffi-
ciently impact the quality of life in the elderly in a previous
study (46). The improvement of pain as measured by the SF-
36 in our study suggests an association between OSAS and
the activation of inflammatory pathways and a reversal of
OSAS by CPAP treatment (47).
The OSAS group exhibited fragmented sleep, increased
light sleep, reduced slow-wave sleep, and reduced REM
sleep on the PSG. These results are consistent with those
reported in the literature (48).
CPAP treatment tended to decrease ESS scores, suggest-
ing that this treatment is effective and supporting its
probable association with the improvement in the quality
of sleep observed in previous studies (36,49).
No differences in hypothyroidism, diabetes, and dyslipi-
demia were observed between the two groups; however, the
prevalence of hypertension was higher in the OSAS group.
All of our patients and control subjects received hyperten-
sion treatment, and blood pressure levels were controlled
for as a comorbidity. This difference has been reported
previously, and it highlights the association between OSAS
and cardiovascular diseases (11). This association may
influence OS. OS is associated with endothelial dysfunction
and metabolic syndrome, which leads to cardiovascular
diseases. However, OSAS is frequently complicated by
metabolic syndrome (50). OSAS and metabolic syndrome
may exert negative synergistic effects on the cardiovascular
system through multiple mechanisms (e.g., intermittent
hypoxia, sleep disruption, and activation of the sympathetic
nervous system and inflammatory mediators) (51), which
may be related to OS.
Our study demonstrated that elderly patients with OSAS
may benefit from CPAP treatment, which improved sleep
parameters, contributed to the reversal of OS and enhanced
the patients’ quality of life.
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Hcy mmol/L 9.6 (7.8-11.4) 11.0 (8.7-13.4) 12.1 (11.0-13.2) 12.1 (10.7-13.5)
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control and OSAS groups, ‘ p,0.05 for the comparison between the final values for the control and OSAS groups. (GLM test).
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